Oncothyreon off as Stimuvax NSCLC data delayed

Oncothyreon Inc. (NASDAQ:ONTY) fell $3.34 (40%) to $5.07 on Tuesday on news that data from the Phase III START trial of Stimuvax in non-small cell lung cancer will not be available until early 2013, instead of 2H12 as previously expected. Partner Merck KGaA (Xetra:MRK) revised the guidance after an IDMC recommended START continue to completion based on a second interim analysis. ...